MX2017010793A - Terapeuticos de anticuerpo que ligan cd137. - Google Patents

Terapeuticos de anticuerpo que ligan cd137.

Info

Publication number
MX2017010793A
MX2017010793A MX2017010793A MX2017010793A MX2017010793A MX 2017010793 A MX2017010793 A MX 2017010793A MX 2017010793 A MX2017010793 A MX 2017010793A MX 2017010793 A MX2017010793 A MX 2017010793A MX 2017010793 A MX2017010793 A MX 2017010793A
Authority
MX
Mexico
Prior art keywords
antibodies
derivatives
polypeptides
methods
fragments
Prior art date
Application number
MX2017010793A
Other languages
English (en)
Inventor
Zhou Heyue
Dixon Gray John
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MX2017010793A publication Critical patent/MX2017010793A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen composiciones y métodos que se refieren a o se derivan de anticuerpos anti-CD 137. De manera más específica, se describen anticuerpos completamente humanos que ligan CD137, fragmentos que ligan anticuerpo-CD137 y derivados de tales anticuerpos y polipéptidos que ligan CD137 comprendiendo tales fragmentos. Aún más, se describen ácidos nucleicos que codifican tales anticuerpos, fragmentos de anticuerpos y derivados y polipéptidos, células que comprenden tales polinucleótidos, métodos para hacer tales anticuerpos, fragmentos de anticuerpos y derivados y polipéptidos, y métodos para usar tales anticuerpos, fragmentos de anticuerpos y derivados y polipéptidos, incluyendo métodos para tratar enfermedad que requiere ya sea estimulación de respuestas inmunes o supresión. Las enfermedades dóciles a tratamiento se seleccionan del grupo que consiste de cáncer, enfermedades autoinmunes e infecciones virales.
MX2017010793A 2015-02-22 2016-02-22 Terapeuticos de anticuerpo que ligan cd137. MX2017010793A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562119211P 2015-02-22 2015-02-22
PCT/US2016/018897 WO2016134358A1 (en) 2015-02-22 2016-02-22 Antibody therapeutics that bind cd137

Publications (1)

Publication Number Publication Date
MX2017010793A true MX2017010793A (es) 2018-07-06

Family

ID=56690285

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010793A MX2017010793A (es) 2015-02-22 2016-02-22 Terapeuticos de anticuerpo que ligan cd137.

Country Status (12)

Country Link
US (4) US10259881B2 (es)
EP (1) EP3258959A4 (es)
JP (1) JP2018508509A (es)
KR (1) KR20180016972A (es)
CN (1) CN107921104A (es)
AR (1) AR105313A1 (es)
AU (1) AU2016219772A1 (es)
CA (1) CA2977257A1 (es)
IL (1) IL254088A0 (es)
MX (1) MX2017010793A (es)
TW (1) TW201632559A (es)
WO (1) WO2016134358A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
EP3258959A4 (en) 2015-02-22 2018-10-17 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137
EP3988577A1 (en) * 2015-05-21 2022-04-27 Alligator Bioscience AB Anti-cd137 antibodies
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
MA45672A (fr) 2016-07-14 2019-05-22 Biontech Ag Anticorps multispécifiques dirigés contre cd40 et cd137
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
WO2018098370A1 (en) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
EP3523332B1 (en) * 2017-01-06 2021-12-29 Eutilex Co., Ltd. Anti-human 4-1 bb antibodies and use thereof
CN109963570A (zh) 2017-01-21 2019-07-02 宁波知明生物科技有限公司 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
MX2019012223A (es) * 2017-04-13 2019-12-09 Agenus Inc Anticuerpos anti-cd137 y metodos de uso de los mismos.
TWI820031B (zh) 2017-07-11 2023-11-01 美商坎伯斯治療有限責任公司 結合人類cd137之促效劑抗體及其用途
BR112020001441A2 (pt) 2017-08-01 2020-08-04 Eli Lilly And Company anticorpos anti-cd137
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
SG11202002982YA (en) * 2017-10-10 2020-04-29 Numab Therapeutics AG Multispecific antibody
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
TWI701259B (zh) * 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
CN111741976A (zh) 2017-12-19 2020-10-02 F星贝塔有限公司 包括pd-l1抗原结合位点的fc结合片段
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
BR112020014576A2 (pt) * 2018-02-23 2020-12-08 Bicycletx Limited Ligantes peptídicos bicíclicos multiméricos
CA3099308A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
EP3814377A2 (en) * 2018-06-29 2021-05-05 Alector LLC Anti-sirp-beta1 antibodies and methods of use thereof
EP3823988A1 (en) * 2018-07-19 2021-05-26 Eli Lilly and Company Bispecific antibodies targeting immune checkpoints
WO2020052581A1 (en) 2018-09-12 2020-03-19 Eucure (Beijing) Biopharma Co., Ltd Anti-tnfrsf9 antibodies and uses thereof
CN113166262A (zh) 2018-10-11 2021-07-23 英伊布里克斯公司 Pd-1单结构域抗体及其治疗组合物
CN113286825B (zh) * 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途
EP3906056A4 (en) * 2019-01-02 2023-02-08 QLSF Biotherapeutics Inc. CD137 AGONIST ANTIBODIES AND USES THEREOF
MX2021010281A (es) * 2019-02-26 2021-09-23 Sorrento Therapeutics Inc Proteinas de enlace a antigenos que se enlazan al bcma.
US20230135930A1 (en) 2019-04-24 2023-05-04 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP3980448A4 (en) * 2019-06-04 2023-06-28 Academia Sinica Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
CA3144617A1 (en) * 2019-06-26 2020-12-30 Ap Biosciences, Inc. Antibodies for t-cell activation
US11466086B2 (en) 2019-10-11 2022-10-11 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1BB and uses thereof
US20230068663A1 (en) * 2020-02-05 2023-03-02 The Board Of Regents Of The University Of Texas System Novel lilrb2 antibodies and uses thereof
US20230285555A1 (en) * 2020-04-17 2023-09-14 Dingfu Biotarget, Co., Ltd. Preparation specifically bound with cd137 and use thereof
CN113842456B (zh) * 2020-06-28 2022-07-26 上海齐鲁制药研究中心有限公司 一种抗人4-1bb的单克隆抗体制剂及其用途
WO2023098785A1 (zh) * 2021-12-01 2023-06-08 上海君实生物医药科技股份有限公司 抗4-1bb抗体及其用途
CN115975032B (zh) * 2022-12-19 2024-06-07 华润生物医药有限公司 一种cldn18.2抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (en) * 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
ES2328025T3 (es) * 2001-10-09 2009-11-06 Mayo Foundation For Medical Education And Research Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb.
US20030223989A1 (en) * 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP1851244A4 (en) 2005-02-15 2009-04-15 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF
PL2614082T3 (pl) * 2010-09-09 2019-02-28 Pfizer Inc. Cząsteczki wiążące 4-1BB
PT2644698T (pt) * 2010-11-17 2018-01-31 Chugai Pharmaceutical Co Ltd Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP3258959A4 (en) 2015-02-22 2018-10-17 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137
TW201639888A (zh) 2015-03-06 2016-11-16 索倫多醫療公司 結合ｔｉｍ３之抗體治療劑
CN112789294A (zh) * 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
CN113166262A (zh) * 2018-10-11 2021-07-23 英伊布里克斯公司 Pd-1单结构域抗体及其治疗组合物

Also Published As

Publication number Publication date
KR20180016972A (ko) 2018-02-20
US20170226215A1 (en) 2017-08-10
IL254088A0 (en) 2017-10-31
WO2016134358A1 (en) 2016-08-25
US11180568B2 (en) 2021-11-23
TW201632559A (zh) 2016-09-16
US20160244528A1 (en) 2016-08-25
US20220025064A1 (en) 2022-01-27
CA2977257A1 (en) 2016-08-25
EP3258959A1 (en) 2017-12-27
US10259881B2 (en) 2019-04-16
US10233251B2 (en) 2019-03-19
JP2018508509A (ja) 2018-03-29
AU2016219772A1 (en) 2017-09-21
US20190161554A1 (en) 2019-05-30
AR105313A1 (es) 2017-09-27
CN107921104A (zh) 2018-04-17
EP3258959A4 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
MX2017010793A (es) Terapeuticos de anticuerpo que ligan cd137.
MX2022011935A (es) Terapeuticos de anticuerpo que se unen a ctla4.
WO2016144803A3 (en) Antibody therapeutics that bind tim3
WO2017015560A3 (en) Antibody therapeutics that bind lag3
WO2016164669A3 (en) Antibody therapeutics that bind cd38
WO2016141328A3 (en) Antibody therapeutics that bind cd47
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
PH12017501347A1 (en) Agonistic icos binding proteins
MY194642A (en) Antibodies binding to cd3
NZ754051A (en) Novel antibodies and uses thereof
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
MY181106A (en) Anti-lag3 antibodies and uses thereof
MY194928A (en) Factor xi antibodies and methods of use
MX2017002381A (es) Proteinas de union de antigeno que se unen a cxcr5.
WO2016164657A3 (en) Antibody therapeutics that bind cd123
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
MY194997A (en) Anti-ccr7 antibody drug conjugates
MX2022015197A (es) Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
MX2019000135A (es) Anticuerpos anti-transicion mesenquimal-epitelial (met) y usos de los mismos.
MX2022002315A (es) Anticuerpos anti-cd96 y sus metodos de uso.
MX2017011600A (es) Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.
MA39847A (fr) Protéines de liaison à l'antigène se liant à wisp1
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies